Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices

NCT01012739 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: Indacaterol 150 μg via the Concept1 dry-powder inhaler
DRUG: Indacaterol 60 μg via the Simoon dry-powder inhaler
DRUG: Indacaterol 120 μg via the Simoon dry-powder inhaler
DRUG: Placebo to indacaterol via the Concept1 dry-powder inhaler

Sponsor

Novartis Pharmaceuticals